Monthly Archives: February 2017

 Biopharmaceutical News Week # 5.2017

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com       Mergers, Acquisitions and Joint Ventures   Biogen spun out its hematology franchise into a standalone public company named Bioverativ which possesses two marketed drugs Eloctate efmorocotocog alpha for hemophilia A and Aprolix efmorocotocog alpha for hemophila as well as a preclinical pipeline. The […]

read more

Biopharmaceutical News Week # 4.2017

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com     Mergers, Acquisitions and Joint Ventures   Johnson & Johnson acquires Actelion (Allschwil, Switzerland) for $30 billion.After weeks of exclusive talks, both companies have entered into a definitive transaction agreement under which the J&J will launch an all-cash tender offer to acquire all of the […]

read more